Peer-reviewed veterinary case report
Risk of bad reactions to milbemycin oxime in dogs with ABCB1-1 Delta
By Barbet, Joy L et al.·Published in Veterinary dermatology·2009·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: ABCB1-1 Delta (MDR1-1 Delta) genotype is associated with adverse reactions in dogs treated with milbemycin oxime for generalized demodicosis.
- Species:
- dog
Plain-English summary
A group of 22 dogs with a skin condition called generalized demodicosis (a type of mange) were treated with a medication called milbemycin oxime. Some of these dogs, especially those from herding breeds, were at risk for serious side effects due to a genetic mutation known as the ABCB1-1 Delta genotype. After treatment, two dogs with this mutation showed signs of neurological toxicity, like unsteady movements, while none of the dogs without the mutation had any adverse reactions. Testing for this genetic mutation before starting treatment could help prevent these harmful side effects.
People also search for: dog skin condition treatment · milbemycin oxime side effects · herding breed medication risks
Abstract
Twenty-two dogs diagnosed with generalized demodicosis were treated with milbemycin oxime (MO) because of poor response to previous therapies or because the dog was a breed known to be susceptible to ivermectin toxicosis. Fifteen of the 22 dogs were herding breeds. Doses of MO ranged from 1.0 to 2.2 mg kg(-1) day(-1) per os. Cheek swab samples were obtained in order to determine each dog's ABCB1 genotype. Adverse drug reactions were recorded for each dog by the owners and/or veterinarians. The ABCB1-1 Delta genotype was significantly associated with the development of an adverse reaction (neurological toxicity) after treatment with MO. None of the 19 dogs with the wild-type ABCB1 allele experienced adverse reactions, whereas two dogs homozygous for the ABCB1-1 Delta mutation developed ataxia. Assessing the ABCB1-1 Delta genotype prior to MO administration may prevent neurological toxicity in these patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19171022/